Skinalar-N0.025%+0.5%

Skinalar-N is a topical combination product containing a mid-potency corticosteroid (fluocinolone acetonide) and an aminoglycoside antibiotic (neomycin sulfate). It is indicated for the relief of inflammatory manifestations of corticosteroid-responsive dermatoses when secondary bacterial infection is present or considered likely.

Established uses

• Infected or potentially infected eczema (atopic, contact, or nummular dermatitis)
• Infected seborrheic dermatitis
• Infected intertrigo (skin-fold dermatitis)
• Secondarily infected insect bite reactions and infected dermatitis of the ear (otitis externa with intact eardrum, where a topical preparation is prescribed for the external ear)

Not appropriate uses

Skinalar-N is not indicated for primary bacterial skin infections without an inflammatory dermatosis (a plain topical antibiotic is preferred), for fungal or viral skin infections, or for long-term/unsupervised use on uncomplicated dermatitis where a corticosteroid alone would suffice.

Each gram of Fluocinolone Acetonide + Neomycin Sulfate topical cream/ointment typically contains Fluocinolone Acetonide (a synthetic corticosteroid, commonly 0.025% w/w) and Neomycin Sulfate (an aminoglycoside antibiotic, commonly 0.5% w/w) in a suitable cream or ointment base. Strength and exact base may vary by manufacturer and locally marketed formulation.

Skinalar-N is a fixed-dose topical combination that pairs the anti-inflammatory, antipruritic, and vasoconstrictive actions of a corticosteroid with the broad Gram-negative (and some Gram-positive) antibacterial coverage of an aminoglycoside. It is formulated as a cream or ointment for external application to the skin, intended for short courses in inflamed dermatoses that are infected or at meaningful risk of secondary bacterial infection.

Skinalar-N belongs to the therapeutic class of topical corticosteroid–antibiotic combinations, used in dermatology for inflammatory skin conditions complicated by bacterial infection.

Fluocinolone acetonide is a synthetic fluorinated corticosteroid that diffuses across cell membranes and binds intracellular glucocorticoid receptors, inducing anti-inflammatory proteins (e.g., lipocortins) that inhibit phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis. This produces anti-inflammatory, antipruritic, and vasoconstrictive effects in the skin.

Neomycin sulfate is an aminoglycoside antibiotic that binds the bacterial 30S ribosomal subunit, causing misreading of mRNA and inhibition of protein synthesis, which is bactericidal against many aerobic Gram-negative organisms and some Gram-positive organisms.

Together in Fluocinolone Acetonide + Neomycin Sulfate, the corticosteroid controls inflammation and pruritus while the antibiotic component treats or helps prevent secondary bacterial infection in the same lesion.

For external (topical) use only. Clean and dry the affected area before application. Apply a thin film of Skinalar-N and gently massage in. Wash hands after application unless the hands are the area being treated. Avoid contact with the eyes, mouth, and mucous membranes. Do not bandage, wrap, or cover the treated area tightly unless a physician specifically instructs occlusive use.

Formal drug-interaction studies with Skinalar-N are limited, but the following are clinically relevant:

• Other topical or systemic corticosteroids: concurrent use over large areas may increase the risk of systemic corticosteroid effects and HPA-axis suppression.
• Other topical products on the same site (e.g., keratolytics, other antibiotics): may alter local absorption or increase irritation; avoid layering multiple topical agents on the same area without medical advice.
• Systemic aminoglycosides or other ototoxic/nephrotoxic drugs: concurrent use is generally not a concern with limited topical use, but should be avoided in patients receiving systemic aminoglycosides or in extensive/prolonged topical use, due to a theoretical additive risk of ototoxicity/nephrotoxicity from systemic absorption of neomycin.

Local adverse effects are more common than systemic ones with Skinalar-N:

• Burning, stinging, itching, or irritation at the application site
• Dryness or folliculitis
• Skin atrophy, striae, telangiectasia, or hypopigmentation with prolonged use
• Allergic contact dermatitis or sensitization to neomycin (a well-recognized risk with repeated use)
• Acneiform eruptions or perioral dermatitis with prolonged facial use
• Rarely, with extensive or prolonged use: systemic corticosteroid effects (HPA-axis suppression, Cushingoid features) or systemic aminoglycoside effects (ototoxicity/nephrotoxicity)

Adequate, well-controlled studies of Skinalar-N in pregnant women are lacking. Topical corticosteroids can be absorbed systemically, and systemic aminoglycosides have been associated with fetal ototoxicity, though systemic absorption from limited topical neomycin use is generally low. Skinalar-N should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus; avoid use over large areas, for prolonged periods, or under occlusion. It is not known whether topical fluocinolone acetonide or neomycin sulfate is excreted in human milk in clinically significant amounts; caution is advised, and application to the breast area should be avoided before breastfeeding. Consult a physician before use during pregnancy or breastfeeding.

Use Skinalar-N only on the skin, for the shortest duration necessary to control symptoms:

• Skin atrophy and systemic absorption: prolonged or extensive use, use under occlusive dressings, application to a large body surface area, or use on thin-skinned regions (face, groin, axillae, skin folds) increases the risk of local skin atrophy, striae, and systemic corticosteroid absorption leading to HPA-axis suppression.
• Neomycin sensitization: prolonged use increases the risk of contact sensitization to neomycin; discontinue if irritation, sensitization, or worsening of the condition occurs.
• Broken or extensively damaged skin: avoid use over large areas of broken or denuded skin because of increased systemic absorption of neomycin and associated (though generally low with topical use) risk of ototoxicity or nephrotoxicity.
• Not for unsupervised long-term use: re-evaluate the diagnosis if no improvement occurs within 1–2 weeks; long-term unsupervised use is not recommended.
• Avoid contact with the eyes. Not for use in the ear if the eardrum is perforated unless specifically directed by a physician.

Topical overdose or accidental ingestion of Skinalar-N is unlikely to cause serious toxicity from a small amount, but excessive or prolonged use can lead to systemic corticosteroid effects (HPA-axis suppression, Cushingoid features) or, rarely, systemic aminoglycoside toxicity (ototoxicity, nephrotoxicity) if absorption is significant. If accidental ingestion occurs, or if signs of systemic toxicity (unusual fatigue, hearing changes, decreased urination) develop, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment.

Store at room temperature (below 30°C), away from light and moisture. Keep the tube or container tightly closed and out of reach of children.

Pediatric use

Skinalar-N may be used in children under medical supervision, generally for the shortest duration and smallest area necessary, because children have a higher skin-surface-to-body-weight ratio and are more susceptible to HPA-axis suppression and other systemic effects from topical corticosteroids and neomycin absorption. Safety and efficacy in neonates and infants for extended use have not been well established; use in this age group requires close physician supervision.

Elderly

Elderly patients often have thinner skin and may be more prone to skin atrophy and bruising with corticosteroid use; use the lowest effective strength and shortest duration.

Renal/hepatic impairment

No specific dose adjustment is established for topical use, but caution is advised in patients with renal impairment because of theoretically increased risk if systemic neomycin absorption occurs (see Precautions and Warnings).

Treatment with Skinalar-N is generally limited to 1–2 weeks. If there is no improvement in that time, or if the condition worsens, the physician should reassess the diagnosis and treatment plan. Prolonged, unsupervised, or repeated courses are not recommended because of the increased risk of skin atrophy, systemic absorption, and neomycin sensitization.

Topical corticosteroid and aminoglycoside antibiotic combination (dermatological anti-infective/anti-inflammatory).

Fluocinolone Acetonide + Neomycin Sulfate works through two complementary mechanisms: fluocinolone acetonide binds glucocorticoid receptors to suppress local inflammatory mediator release, reducing redness, swelling, and itching; neomycin sulfate binds the bacterial 30S ribosomal subunit to inhibit protein synthesis, killing or suppressing susceptible bacteria that commonly cause secondary infection in inflamed skin.

Skinalar-N may be used in children under a physician's direction, but with extra caution: children absorb topical medications more readily relative to body weight, increasing the risk of HPA-axis suppression from the corticosteroid component and systemic effects from neomycin. Use should be limited to the smallest effective amount, the least potent effective regimen, and the shortest duration, with regular medical follow-up. Safety and efficacy of long-term or unsupervised pediatric use have not been established.